EP Patent

EP2611794A1 — 4-azolylaminoquinazoline derivatives and methods of use thereof

Assigned to Ambit Bioscience Corp · Expires 2013-07-10 · 13y expired

What this patent protects

Provided herein are 4-azolylaminoquinazoline compounds for treatment of JAK kinase mediated diseases, including JAK2 kinase-, JAK3 kinase- or TYK2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds a…

USPTO Abstract

Provided herein are 4-azolylaminoquinazoline compounds for treatment of JAK kinase mediated diseases, including JAK2 kinase-, JAK3 kinase- or TYK2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.

Drugs covered by this patent

Patent Metadata

Patent number
EP2611794A1
Jurisdiction
EP
Classification
—
Expires
2013-07-10
Drug substance claim
No
Drug product claim
No
Assignee
Ambit Bioscience Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.